A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This research study is being done in people with advanced-stage solid tumor cancer. Advanced
stage solid tumor cancer is a cancer that forms an abnormal mass of tissue that usually does
not contain cysts or liquid areas. Different types of solid tumors are named for the type of
cells that form them. Examples of solid tumors include lung cancer, breast cancer, prostate
cancer, kidney cancer, colorectal cancer, melanoma and sarcoma.
The purpose of this research study is to evaluate the safety of the investigational study
drug, FN-1501, at different dose levels. FN-1501 has not previously been given to human
subjects. It is intended for the treatment in this study of patients with advanced solid
tumor cancers. This study will determine the effects, good and/or bad, on patients' cancer.
The main objective of this study is to define the recommended phase 2 dose (RP2D) and maximum
tolerated dose (MTD) of FN-1501. The MTD is the highest dose a person can take without having
bad side effects, and the RP2D will be the dose of FN-1501 used in future studies.
Phase:
Phase 1
Details
Lead Sponsor:
Shanghai Fosun Pharmaceutical Development Co, Ltd.